^
Association details:
| Biomarker: | FGFR1 amplification + HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Lytgobi (futibatinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification
Published date:
12/02/2023
Excerpt:
Here, we report final efficacy and safety data for the cohort of patients receiving futibatinib plus fulvestrant for HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification….PFS at 6 months was observed in 10 (45.5%) patients (95% CI: 24.4, 67.8) and the median PFS was 7.2 (95% confidence interval [CI]: 2.1, 7.6) months. Four patients had a confirmed partial response (ORR:18.2%; 95% CI: 5.2, 40.3).
Secondary therapy:
fulvestrant
Trial ID:
